{"id":3573,"date":"2026-05-11T17:00:00","date_gmt":"2026-05-11T15:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=4a87f2403860e214acc8eba59b2304ec"},"modified":"2026-05-11T17:00:00","modified_gmt":"2026-05-11T15:00:00","slug":"avenacy-announces-launch-of-ready-to-use-tranexamic-acid-in-0-7-sodium-chloride-injection-in-the-u-s-market","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=3573","title":{"rendered":"Avenacy Announces Launch of Ready-to-Use Tranexamic Acid in 0.7% Sodium Chloride Injection in the U.S. Market"},"content":{"rendered":"

\nRepresents the Company\u2019s 27th product launch since inception in October 2023<\/i><\/p><\/a><\/a><\/a><\/a>

SCHAUMBURG, Ill.--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Tranexamic Acid in 0.7% Sodium Chloride Injection in the United States. The product contains the same active ingredient as CYKLOKAPRON\u00ae<\/sup>, as approved by the U.S. Food and Drug Administration, and is indicated for use in patients with hemophilia for short-term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. Each vial of Tranexamic Acid in 0.7% Sodium Chloride Injection contains 1,000 mg per 100 mL (10 mg per mL) and is available as a carton of 10 single-dose ready-to-use vials.<\/p>

\n\u201cWe are proud to continue expanding our portfolio with the addition of Tranexamic Acid in a ready-to-use format,\u201d said Jeff Yordon, Co-Founder and CEO of Avenacy. \u201cThis presentation enables healthcare providers to deliver safe and efficient care while helping reduce preparation time and potential medication errors, reinforcing our long-standing value proposition as a trusted partner to hospitals and providers.\u201d<\/p>

\nIn line with Avenacy\u2019s mission to champion patient safety and streamline patient care, Tranexamic Acid in 0.7% Sodium Chloride Injection will feature the Company\u2019s highly differentiated packaging and labeling to support accurate medication selection.<\/p>

\nAvenacy will begin shipping Tranexamic Acid in 0.7% Sodium Chloride Injection to wholesale partners this week. The Company is supported by a global network of development and contract manufacturing partners that have undergone successful FDA inspections based on cGMP standards.<\/p>

\nU.S. sales of Tranexamic Acid Injection were approximately $30.2 million for the twelve months ending in March 2026, with ready-to-use presentations accounting for approximately $15 million of total sales.1<\/sup><\/p>

\nIndications<\/b><\/p>

\nTranexamic Acid Injection is indicated in patients with hemophilia for short-term use (two to eight days) to reduce or prevent hemorrhage and to reduce the need for replacement therapy during and following tooth extraction.<\/p>

\nContraindications<\/b><\/p>

\nTranexamic Acid Injection is contraindicated:<\/p>